Supplementary Figure S4. Clinical impact of CD49d bimodal expression on durability of BTKi therapy.
No takes yet. Share an insight, caveat, or question.
Alsadhan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: